Gerresheimer AG partners with Finnish start-up Adamant Health Oy to advance personalized treatment solutions for Parkinson's disease through innovative measurement and monitoring technology.
Information on the Target
Adamant Health Oy is a Finnish MedTech start-up and a spin-off from the University of Eastern Finland, focusing on the development of innovative solutions for the management of Parkinson’s disease. With over 15 years of academic research expertise in the field, the company aims to transform Parkinson’s therapy through advanced measurement and analysis technologies that enhance individualized treatment plans and significantly improve patients' quality of life.
The firm's primary objective is to address one of the major challenges faced by Parkinson's patients: effectively determining the optimal time for medication intake to alleviate symptoms. By integrating sophisticated measurement systems with real-time data analysis, Adamant Health is committed to helping patients achieve more stable and predictable symptom management.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Finland
Finland has established itself as a leader in healthcare innovation, particularly in the MedTech sector. The country is known for its robust research foundations, collaboration between academia and industry, and
Similar Deals
Fåhraeus Startup & Growth FSG Fund II → Aplagon Oy
2025
Gerresheimer AG
invested in
Adamant Health Oy
in 2022
in a Seed Stage deal